Stay updated with breaking news from Daniel Feikin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/D6LU6OZLKVNWTJXRT6M4HMCVIE.jpg)
Advisers to the U.S. Food and Drug Administration on Thursday backed the safety and effectiveness of Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine, boosting its chances of becoming the first available maternal shot to protect babies from the illness.
The FDA, which typically follows the independent committee's recommendations, is scheduled to decide on approval of the vaccines by May.
Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults against the respiratory illness known as RSV.
Federal health advisers on Tuesday narrowly backed an experimental vaccine from Pfizer that could soon become the first shot to protect older adults
Federal health advisers have narrowly backed an experimental vaccine from Pfizer that could become the first shot to protect older adults against the respiratory illness known as RSV. A panel of Food and Drug Administration advisers voted 7-4 in favor of the shot's safety and effectiveness for people 60 and older. The recommendation is non-binding and the FDA will make its own decision on the vaccine. For most healthy people, RSV is a cold-like nuisance. But the virus can be dangerous for young children and the elderly. Pfizer and GlaxoSmithKline are each seeking FDA approval for two new ...